Mylan Offers “$0 Co-Pay Offer” for EpiPen

The folks at Mylan have some very exciting news that I’m exited to share with you…and your wallet.  Thanks to Jennifer and Mylan for allowing me to share the below press release with my fabulous readers!


Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector

Marketer of EpiPen® Auto-Injector, the No. 1 prescribed epinephrine auto-injector, announces additional efforts to increase anaphylaxis awareness, preparedness and access to treatment for those affected by life-threatening allergies

BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ — Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), is celebrating the 25th anniversary of the U.S. Food and Drug Administration’s (FDA) approval of the EpiPen® (epinephrine) Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector.

In recognition of this important milestone, Mylan Specialty recently introduced the 25th anniversary “$0 Co-Pay Offer.” As is consistent with Mylan’s commitment to providing people access to high quality medicine, this co-pay card is available to both cash-paying and commercially insured patients. Certain restrictions apply. Additional information about the co-pay card is available online at, and the coupon is available to patients through physicians across the country. The “$0 Co-Pay Offer” is valid for up to three EpiPen 2-Pak® cartons or EpiPen Jr 2-Pak® cartons per prescription, as patients may need to access two EpiPen or EpiPen Jr® (epinephrine) Auto-Injectors in multiple locations. Eligible patients can use the offer with an unlimited number of prescriptions until the coupon offer expires on December 31, 2013.

“Mylan has a long-standing dedication to increasing access to epinephrine auto-injectors through innovative access solutions such as the EpiPen4Schools program, and we’re pleased to continue that commitment by introducing our $0 Co-Pay Offer,” said Heather Bresch , CEO of Mylan.

To read more of this press release, please click here.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s